MARTINSRIED, Germany--(BUSINESS WIRE)--Proteros biostructures GmbH (Martinsried, Germany) today announced it has signed a research services agreement with UCB (Brussels, Belgium) where Proteros will support the structure-based discovery of small molecule drugs.
In the initial stage of the programme, Proteros will leverage its expertise in gene-to-structure projects and its proprietary technologies to solve the three dimensional structure of an undisclosed target together with its related proteins.
After the establishment of these crystallography systems, Proteros will screen fragments and compounds supplied by UCB with the objective of solving high resolution X-ray structures of the fragments and compounds to confirm the binding modes to the proteins, and therefore facilitating the medicinal chemistry and optimisation of small molecules.
Dr. Torsten Neuefeind, Proteros’ Chief Executive Officer, commented: “We are very pleased to extend our successful relationship which we first entered in 2007, and now to be considered a key partner for UCB in this important project with UCB New Medicines™.”
The financial terms of the fixed research fees and milestones are not disclosed.
About Proteros biostructures GmbH:
Proteros biostructures is a privately held company, which provides services and unique technologies to support drug discovery within life sciences. The company accelerates and improves protein structure analysis and structure-based drug discovery by its expertise, industrialised process and unique technologies for crystallography and fragment screening. Proteros complements its clients’ internal capabilities with its external expertise and access to flexible resources. Proteros currently provides services to over sixty pharmaceutical and biotechnology companies in North America, Europe and Japan. More information about Proteros can be found on the company’s website at www.proteros.com.
Proteros biostructures GmbH
Dr. Peter Reinemer, Executive VP Scientific Marketing